1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors - Wikidata - awgldk - TriplyDB

1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors

1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors

http://www.wikidata.org/entity/Q24645072

about

The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones The toxicology of bath salts: a review of synthetic cathinones Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)Pharmacological characterization of designer cathinones in vitro NPS: Medical Consequences Associated with Their Intake Substituted methcathinones differ in transporter and receptor interactions From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.Stereoselective Actions of Methylenedioxypyrovalerone (MDPV) To Inhibit Dopamine and Norepinephrine Transporters and Facilitate Intracranial Self-Stimulation in Rats.Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs Emerging drugs of abuse: current perspectives on substituted cathinones.Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish internet company.3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry.Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.Analytical characterization of three trifluoromethyl-substituted methcathinone isomers.Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones.Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter Synthetic cathinones and their rewarding and reinforcing effects in rodents.Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery.Toxicity and death following recreational use of 2-pyrrolidino valerophenone."Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter.The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).Test purchase, identification and synthesis of 2-amino-1-(4-bromo-2, 5-dimethoxyphenyl)ethan-1-one (bk-2C-B).Baths salts, spice, and related designer drugs: the science behind the headlines.Identification of phase I and II metabolites of the new designer drug α-pyrrolidinohexiophenone (α-PHP) in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS).Neurotoxicity Induced by Mephedrone: An up-to-date Review.Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence.Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation "bath salts," on intracranial self-stimulation thresholds in rats.Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention.Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice.Psychoactive "bath salts": not so soothing.Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV).The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.

P2860

Q24615008-06580334-A0D8-489C-854A-05844F65B12D Q24621938-729EF42A-1E3F-4046-A270-2778BB90C631 Q28249380-3C1AA175-87A4-49A0-BB11-4B5304A2B023 Q28253719-4A559A65-CA44-4134-A4A6-F15E62A0B4ED Q28270808-21B11F33-4E05-41A7-84CF-E1C23BD857BA Q28273207-A7A268AF-A722-4085-BE84-000E5E9A6944 Q28276182-D6E37D64-77F8-4F64-9B9B-E46BAD70F14B Q28288908-05CBE3E9-AB09-4826-AA31-38BE1B78289E Q28596136-C9AE00F2-C91A-4F9C-AC90-1B87913F3C95 Q30535782-F879D780-B70C-41E2-8FD0-24E76B7B6F99 Q30841838-292B77C9-4AA5-45B9-95E1-C7A0BA4485FA Q33566201-A856FC2F-1E44-41F4-AA95-1E7A3C613D50 Q33706892-1C178800-2F37-4BE2-BB0E-A03653B0F4C5 Q34079088-5127CB14-2CB6-4779-BF62-7759217C49CC Q34115248-76D0FEA2-E858-44F1-89F8-724C2687B66F Q34122902-7E78FE3D-CD97-43D3-9A99-26D396106150 Q34149434-673BC7B4-1185-4E8F-BAB6-FFA803CCAAB2 Q34169500-7BE7F405-5CA9-4E5E-BF54-326247086882 Q34280393-30684134-C7BD-4082-BD9F-4EF5B3027689 Q34325588-66F16AB9-FFFA-4ACE-8B78-6529AF5C603E Q34352354-6D934681-9D65-4EB8-87D8-1376696C8DC7 Q34367145-D5DEE07E-0993-4B59-8FEB-A867E55D3A25 Q34376624-3F43A521-4B7F-4C72-B416-1CF7C9F70C3D Q34377086-FA073F7D-E407-4F60-9F77-3D4E2CA3D9A3 Q34377572-EB2C8A3C-7A69-4B3C-BFFA-D64512871861 Q34431632-E9BF92D0-8FEA-42AC-98A9-042606E70446 Q34491601-C1EB3870-9F59-4163-9456-F8426CB0FE59 Q34499556-AD8BB206-6A1F-4ED2-9417-0CF03CE699C0 Q34546425-A101713E-D24D-47DB-ACEE-EED7F7239345 Q34756340-270F9A35-F6AC-4D51-8553-223462D2C0FE Q35203582-820DBA09-6944-4687-9938-2DF4185D2153 Q35754464-7FF3583A-2698-4EF1-9D87-D126BB51E462 Q36227275-2569703C-30F8-404D-B6B8-6B0E1F4B61CA Q36329494-DA91C5B6-1ED4-4FA6-B8DA-63DE4728BBCC Q36509367-CDD2400B-53ED-4078-AB4F-8258E6979218 Q36548946-4E6BEE30-A540-458A-AD90-30D79A229432 Q36571393-8DBF0FF9-EDAF-4ADB-ACE0-BA3DEE7FD0CE Q36610017-C1941B51-0104-423B-884D-3A1100D1B305 Q36709254-B9167D74-63EC-4759-9FEC-19688E266756 Q37168973-0807575A-C34A-498C-AA81-A54DE85184E9

P2860

1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors

http://www.wikidata.org/entity/Q24645072

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@ast

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@en

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@nl

type

label

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@ast

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@en

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@nl

prefLabel

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@ast

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@en

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@nl

P1433

Q24645072-715A9DB9-81E7-44A8-96F5-481D9B3D9711

P1476

Q24645072-18BE2F4B-F5EE-44D1-AEAB-7A77C96B00FE

P2093

Q24645072-0872AD76-983F-4AE6-B7D5-AAF71D1C0A08

Q24645072-1C69244B-31AF-4CAE-AEAA-391407A49C4D

Q24645072-74BFB848-6323-4B34-8DA1-43B81B224629

P2860

Q24645072-033D8379-D569-41CD-ABBA-B1ACF6CEF0B8

Q24645072-04B884E1-4EC4-4581-8BD1-F10EEE9462CA

Q24645072-117B5DFA-CDA4-4208-B6C1-32DEBB082690

Q24645072-1D39FE65-B7C0-4FD1-9C27-37A0D0E515D8

Q24645072-26BFBE10-8BD7-4CCD-819A-8524D1777BBC

Q24645072-2D6A36D9-000D-4EAD-B364-A728882DC67F

Q24645072-34141A4E-A701-4D84-AD25-5F1DC9028412

Q24645072-3C2860DB-496D-4BC4-B1A7-0BED918D7509

Q24645072-44F36930-A2A7-4DE1-8234-DE6317C91404

Q24645072-51773C15-4D9A-4293-8F43-EE16FD2AD59D

P304

Q24645072-A46CC99B-23F5-4D38-915B-0AB779EE7F0E

P31

Q24645072-9AACF3D5-7DE0-47FA-8858-EBC4C827F734

P3181

Q24645072-219865EB-72E9-4A20-A7AF-2D1E21AD1FA8

P356

Q24645072-B71CE737-32BC-4337-A67B-95792219E02D

P407

Q24645072-7A42F98A-2022-48CC-A2F9-8FD0F5CEC15F

P433

Q24645072-515D5808-4877-4E1E-8848-219A84050F1B

P478

Q24645072-35C0D785-D001-4BC5-97DF-786E64AA9892

P50

Q24645072-33DD917E-2AEC-4EAF-A7B7-1001AE89DCF1

P577

Q24645072-0767078E-AC3C-433E-AA18-4917825BC5BB

P5875

Q24645072-B8C6C5CB-2DD3-4717-898C-ADE15DD284E9

P698

Q24645072-3C47F5E4-4D7C-4619-B57B-DFC619BBF7C0

P921

Q24645072-CA01C654-6446-48BC-900A-5613E085BD46

P932

Q24645072-7F8B3119-FA71-4310-87FC-E32C3880291B

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

1-(4-Methylphenyl)-2-pyrrolidi ...... of monoamine uptake inhibitors

@en

P2093

Bertha K Madras

http://www.w3.org/2001/XMLSchema#string

David Butler

http://www.w3.org/2001/XMLSchema#string

Peter C Meltzer

http://www.w3.org/2001/XMLSchema#string

P2860

The catecholamine hypothesis of affective disorders: a review of supporting evidence

Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder

2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy

Evaluation of pyrovalerone in chronically fatigued volunteers

The metabolism of pyrovalerone hydrochloride

Agents in development for the management of cocaine abuse

Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen

Cocaine receptors on dopamine transporters are related to self-administration of cocaine

Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.

P304

1420-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4147656

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM050797A

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey R. Deschamps

P577

2006-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7297309

http://www.w3.org/2001/XMLSchema#string

P698

16480278

http://www.w3.org/2001/XMLSchema#string

P921

P932

2602954

http://www.w3.org/2001/XMLSchema#string